Positive clinical trial results are a strong catalyst for biopharmaceutical companies, as they indicate progress in the drug development pipeline and potential for future revenue growth. The successful Phase 2 study of VX-548 for treating painful diabetic peripheral neuropathy suggests that the drug has a good chance of advancing to later-stage trials and eventually to market, which can be a significant driver of the company's future earnings and stock price.